Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioids

U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Ransdell Pierson  |  March 18, 2016

(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Centers for Disease Control and PreventionChronic painGuidelinesOpioids

Legal Updates: As Opioids for Pain Treatment Come Under Greater Scrutiny, Controlled Substance Agreements Matter More

Steven M. Harris, Esq.  |  March 1, 2013

These contracts can communicate a physician’s expectations for a pain treatment plan and guidelines for safe use by their patients

Filed under:Legal UpdatesPractice Support Tagged with:LegalopioidPainpatient communication

Opioids More Dangerous than other Analgesics for Elderly

Sue Pondrom  |  April 13, 2011

Safety events vary among different opioids

Filed under:AnalgesicsDrug UpdatesResearch Rheum Tagged with:NSAIDsOpioidsPainResearchSafetySteroids

Editor's Pick

Cannabis for Pain Management in Rheumatology

Joanna Zeiger, PhD, & Kaleb Michaud, PhD  |  March 7, 2025

‘Cannabis has a long history of being used for pain management,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘What does it mean for rheumatology patients moving forward? Read our article for one answer to this question.’ As cannabis becomes more widely legalized, both in the U.S. and internationally, its use for pain…

Filed under:ConditionsDrug UpdatesPain SyndromesPatient Perspective Tagged with:Editor's PickJoanna ZeigerKaleb MichaudPhD

The 5 Ms: A Simple Framework to Care for Older Patients

Samantha C. Shapiro, MD  |  December 5, 2024

WASHINGTON, D.C.—For the first time in U.S. history, older adults are projected to outnumber children by 2034, and their care poses unique challenges to the rheumatologist.1 Normal physiologic changes of aging include but aren’t limited to falling renal function, changes in pharmacokinetics and bone density loss. At the ACR Convergence 2024 Review Course, Namrata Singh,…

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024elder care

Cannabis for Pain Relief: An Area Ripe for Research

Vanessa Caceres  |  September 28, 2023

Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:marijuanaPain Syndrome FocusRheum

2024 Proposed Rule for the Quality Payment Program Released

RISE Registry Team  |  August 17, 2023

See key changes for the Merit-Based Incentive Payment System for the 2024 performance year as outlined in the proposed rule.

Filed under:Practice ManagementQuality Assurance/Improvement Tagged with:Medicare Physician Fee Schedule (MPFS)MIPSphysician quality reportingQuality Payment Program (QPP)

Gout Research at a Glance

Lisa Stamp, MBChB, FRACP, PhD  |  November 28, 2022

PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…

Filed under:ConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

Richard Brasington Jr., MD, FACP, MACR  |  November 4, 2022

I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

Filed under:AnalgesicsDrug UpdatesOpinionSpeak Out Rheum Tagged with:opioid crisisPain Syndrome FocusRheumSpeak Out Rheumatology

Some Cannabis Products May Ease Chronic Pain, But Side Effects Are a Concern

Reuters Staff  |  June 15, 2022

NEW YORK (Reuters Health)—Oral synthetic cannabis products that have a high tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio, as well as extracted cannabis products with comparable THC-to-CBD ratios, may provide moderate, short-term improvements in chronic pain, a large systematic review of relevant research suggests.1 However, these products are also associated with higher risks for side effects,…

Filed under:ConditionsPain Syndromes Tagged with:cannabidiol (CBD)Chronic painPainPain Managementtetrahydrocannabinol (THC))

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 20
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences